Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma (Q42153454)

17 October 2017

Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma (English)

1 reference

17 October 2017

0 references

0 references

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Christopher L Marsh

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

8

Tanios Bekaii-Saab

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Laura K Aguilar

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Vincent M Chung

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jon Walker

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Walter Coyle

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Howard Marx

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Gregory B Lesinski

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Benjamin Swanson

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Daniel Sanchez

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Andrea G Manzanera

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Estuardo Aguilar-Cordova

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Mark Bloomston

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

21 March 2015

1 reference

Cancer Immunology, Immunotherapy

17 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

727-736

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25795132%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-015-1679-3

7 June 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Cytotoxic immunotherapy strategies for cancer: mechanisms and clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Pancreatic carcinoma cell killing via adenoviral mediated delivery of the herpes simplex virus thymidine kinase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Adenovirus-mediated gene therapy of experimental gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Immune-dependent distant bystander effect after adenovirus-mediated suicide gene transfer in a rat model of liver colorectal metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Enhanced therapeutic effect of HSV-tk+GCV gene therapy and ionizing radiation for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Systemic effects of local radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Adenovirus-mediated thymidine kinase gene therapy in combination with topotecan for patients with recurrent ovarian cancer: 2.5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Therapeutic endoscopic ultrasonography: intratumoral injection for pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Current status of adjuvant therapy for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3

Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1679-3